Biotech Startups

Blossom provides contract manufacturing and supply chain services for the pharmaceutical and medical cannabis industries in Europe, specializing in narcotics handling, API manufacturing, and logistics for medical cannabis products.

1 investor

Blue Cell Therapeutics develops an off-the-shelf allogeneic stem cell therapy platform (Blue Cells) that promotes angiogenesis and nerve repair, with a lead candidate (BlueC-231) aimed at treating severe erectile dysfunction in men after radical prostatectomy. The company operates in the biotech and cell therapy space, targeting patients unresponsive to existing drug treatments.

1 investor

BlueBank is a biotech company specializing in microbial, molecular, and biochemical engineering technologies for applications in bio-based products, environmental solutions, and aquaculture.

1 investor

BlueCell Bio develops fermentation technologies that break down microalgae cell walls to make Omega-3s and other nutrients more bioavailable, producing sustainable vegan ingredients for human food, animal feed, and pet nutrition. The company is based in Copenhagen, Denmark.

1 investor

Blue Horizon is an investment firm backing founders at the intersection of biology, technology, and agriculture, focusing on creating world-leading platforms through growth and consolidation strategies.

1 investor

Bluejay is a biotechnology company focused on therapeutic development. The page centers on its founder's background in drug discovery and life science venture investing but gives limited detail on the company's specific products.

1 investor

Blue Rock Therapeutics discovers and develops cell therapies to treat disease and improve patient outcomes. The company operates at the frontier of cell therapy science with a focus on innovation and patient impact.

1 investor

BlueStone Venture Partners is a venture capital firm that invests in portfolio companies across multiple sectors, leveraging operational, technical, and financial expertise from its leadership team.

1 investor

Bluewater Bio develops water treatment and environmental engineering solutions, serving clients across construction, industrial, and infrastructure projects globally.

1 investor

BlueWhale Bio develops manufacturing technologies for cell-based therapies, focusing on cell activation and expansion in early-stage processing to improve efficiency and reduce costs. The company serves medical institutions and therapeutics developers working with cell therapy products.

1 investor

BlueWillow Biologics develops an intranasal vaccine delivery platform using novel oil-in-water emulsion technology to address pandemic preparedness, infectious diseases, and food allergies. The company is a clinical-stage biotech firm with proprietary technology originally discovered at the University of Michigan.

1 investor

BMC Ingredients produces Rhiza, a mycelium-based ingredient that serves as a whole-food, complete protein and clean-label additive for food manufacturers. It is used in animal-free products, as a meat enhancer to improve nutrition and mouthfeel, and as a protein and fiber boost in supplements and baked goods.

1 investor

BMI OrganBank develops organ perfusion and preservation systems to improve transplantation outcomes and extend organ viability outside the body. The company serves transplant clinicians and researchers working to reduce organ transplant waitlists and advance regenerative medicine.

1 investor

b.next develops technologies and infrastructure for building synthetic cells from scratch, working with researchers, universities, governments, and funders. It operates Nucleus, an open technology platform providing materials, protocols, documentation, and software for engineering synthetic cells.

1 investor

BnH Research develops therapeutics for chronic conditions with an initial focus on central nervous system disorders such as Alzheimer's Disease, PTSD, addiction, amblyopia, and stroke, with drug candidates aimed at reopening cortical plasticity. It also provides contract-based research services offering drug efficacy validation data to pharmaceutical companies in early-stage drug discovery, based in South Korea.

1 investor

Boca Bio provides biospecimen sourcing for life sciences research through its BioSpecimen360 offering. It serves researchers who need access to biological specimens.

1 investor

Bonray Bio develops miniaturized microscopy optics and AI-powered image analysis software for reproductive medicine diagnostics, providing male infertility diagnostic instruments and consumables to fertility clinics globally.

1 investor

Bonumose produces tagatose, a naturally occurring "rare sugar" made from plant starch (corn, wheat, cassava) using proprietary enzymes, offering a sugar substitute with a low glycemic index and reduced calories. It supplies food manufacturers and consumers with tagatose and other rare ingredients for food, supplements, animal feed, crop protection, and soil health.

1 investor

Bonus Biogroup is a clinical-stage biotechnology company developing tissue engineering and cell therapy products for unmet medical needs related to tissue damage, inflammation, and immune response. Its investigational products include MesenCure, an allogeneic cell therapy targeting inflammation, and BonoFill, a tissue-engineered bone graft for orthopedic and maxillofacial bone defects.

1 investor

Booster Therapeutics develops small-molecule medicines that directly activate the cell's 20S proteasome to restore protein quality-control and clear disease-causing proteins, using its structure-based DGRADX platform combining high-throughput screening, X-ray crystallography, and computational tools. The company is building a multi-disease pipeline initially focused on neurodegenerative diseases.

1 investor

Bora Pharmaceuticals is a pharmaceutical services company offering CDMO (contract development and manufacturing) for both small molecule and large molecule/biologics products, alongside its own drug development focused on specialty pharma and rare diseases. Founded in 2007 and headquartered in Taiwan, it serves pharmaceutical and biotech partners globally.

1 investor

Borea Therapeutics develops gene therapy delivery technologies based on a proprietary AAV conjugation platform targeting neurological and genetic diseases. The company serves the therapeutic biotechnology market with precision neuronal targeting and advanced delivery strategies.

1 investor

Borealis develops RNA medicines to treat kidney diseases. The company was founded by the team behind Chinook Therapeutics, which Novartis acquired in 2023, and focuses on kidney disease indications with unmet medical need.

1 investor

Boston Cell Standards develops calibration and quality-control products (IHCalibrators and IHControls) for immunohistochemistry (IHC) laboratories, used for assay validation, instrument alignment, troubleshooting, and proficiency testing. Its standards serve clinical and research labs and drug developers to maintain consistent IHC test results across sites and trial phases for accurate patient diagnosis and treatment stratification.

1 investor